Kori, MediAydın, BüşraGülfidan, GizemBeklen, HandeKelesoglu, NurdanÇalışkan İşcan, AyşegülTuranli, BesteErzik, CanKarademir, BetulArga, Kazim Yalcin2021-01-112021-01-112021Kori, M., Aydin, B., Gulfidan, G., Beklen, H., Kelesoglu, N., Caliskan Iscan, A., Turanli, B., Erzik, C., Karademir, B., & Arga, K. Y. (2021). The Repertoire of Glycan Alterations and Glycoproteins in Human Cancers. Omics : a journal of integrative biology, 10.1089/omi.2020.0210. Advance online publication. https://doi.org/10.1089/omi.2020.02101536-23101557-8100https://doi.org/10.1089/omi.2020.0210https://hdl.handle.net/20.500.12713/1308Cancer as the leading cause of death worldwide has many issues that still need to be addressed. Since the alterations on the glycan compositions or/and structures (i.e., glycosylation, sialylation, and fucosylation) are common features of tumorigenesis, glycomics becomes an emerging field examining the structure and function of glycans. In the past, cancer studies heavily relied on genomics and transcriptomics with relatively little exploration of the glycan alterations and glycoprotein biomarkers among individuals and populations. Since glycosylation of proteins increases their structural complexity by several orders of magnitude, glycome studies resulted in highly dynamic biomarkers that can be evaluated for cancer diagnosis, prognosis, and therapy. Glycome not only integrates our genetic background with past and present environmental factors but also offers a promise of more efficient patient stratification compared with genetic variations. Therefore, studying glycans holds great potential for better diagnostic markers as well as developing more efficient treatment strategies in human cancers. While recent developments in glycomics and associated technologies now offer new possibilities to achieve a high-throughput profiling of glycan diversity, we aim to give an overview of the current status of glycan research and the potential applications of the glycans in the scope of the personalized medicine strategies for cancer.eninfo:eu-repo/semantics/closedAccessCancerFucosylation and Personalized MedicineGlycanGlycan AlterationGlycoproteinGlycosylationSialylationTumorArticle33404348WOS:0006288999000032-s2.0-85101199640Q210.1089/omi.2020.0210Q2